Citations

Clear

16280 citation(s) found for "Yu, David".

Reply to M. Aapro et al
Steensma, David P. , Sloan, Jeff A. , Loprinzi, Charles L. , Steensma, David P

Mayo Clinic

Journal of Clinical Oncology | May 3, 2011 | Volume: 29 | Issue: 17 | Pages: e527-e528

10.1200/jco.2011.35.4597 Get It

Integrated control of proliferation and differentiation of mesenchymal stem cells.
Filipak, Michiko, Estervig, David N., Tzen, Chin‐Yuan, Minoo, Parviz , Hoerl, Bryan J., Maercklein, Peter B., Zschunke, Michael A., Edens, Maryanne, Scott, R E

Mayo Clinic

Environmental Health Perspectives | April 29, 2011 | Volume: 80 | Issue: No issue available | Pages: 117-125

10.1289/ehp.8980117 | PMID 2647473 Get It

A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway
Zheng, Ying , Qin, Hongwei , Frank, Stuart J. , Deng, Luqin, Litchfield, David W. , Tefferi, Ayalew , Pardanani, Animesh , Lin, Fang‐Tsyr , Li, Jingzhi , Sha, Bingdong , Benveniste, Etty

Mayo Clinic

Blood | April 29, 2011 | Volume: 118 | Issue: 1 | Pages: 156-166

10.1182/blood-2010-01-266320 | PMID 21527517 Get It

AbstractJAK-STAT signaling is involved in the regulation of cell survival, proliferation, and differentiation. JAK tyrosine kinases can be transiently activated by cytokines or growth factors in normal cells, whereas they become constitutively activated as a result of mutations that affect their function in tumors. Specifically, the JAK2V617F mutation is present in the majority of patients with myeloproliferative disorders (MPDs) and is implicated in the pathogenesis of these diseases. In the present study, we report that the kinase CK2 is a novel interaction partner of JAKs and is essential for JAK-STAT activation. We demonstrate that cytokine-induced activation of JAKs and STATs and the expression of suppressor of cytokine signaling 3 (SOCS-3), a downstream target, are inhibited by CK2 small interfering RNAs or pharmacologic inhibitors. Endogenous CK2 is associated with JAK2 and JAK1 and phosphorylates JAK2 in vitro. To extend these findings, we demonstrate that CK2 interacts with JAK2V617F and that CK2 inhibitors suppress JAK2V617F autophosphorylation and downstream signaling in HEL92.1.7 cells (HEL) and primary cells from polycythemia vera (PV) patients. Furthermore, CK2 inhibitors potently induce apoptosis of HEL cells and PV cells. Our data provide evidence for novel cross-talk between CK2 and JAK-STAT signaling, with implications for therapeutic intervention in JAK2V617F-positive MPDs.
Looking into posterior cortical atrophy
Tang‐Wai, David F. , Graff‐Radford, Neill R.

Mayo Clinic

Neurology | April 28, 2011 | Volume: 76 | Issue: 21 | Pages: 1778-1779

10.1212/wnl.0b013e31821ccd4f | PMID 21525423 Get It

Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration
Ingle, JN, Liu, M., Wickerham, D. L., Schaid, DJ, Kubo, M, Costantino, J. P., Goetz, MP, Ames, M, Wang, L, Vogel, V. G., Batzler, Anthony , Flockhart, DA, Nakamura, Yasuya, Weinshilboum, R. M., Ingle, JN, Wickerham, D. Lawrence, Mushiroda, Taisei , Paik, Soonmyung , Flockhart, David A., Wolmark, Norman

Mayo Clinic

Cancer Research | April 27, 2011 | Volume: 70 | Issue: 24_Supplement | Pages: PD05-02-PD05-02

10.1158/0008-5472.sabcs10-pd05-02 Get It

Abstract Background: NSABP P1 and P2 are the largest prevention trials of tamoxifen and raloxifene in women at high risk of developing breast cancer. Both agents have been shown to decrease, but not eliminate breast cancer risk in these women. The goal of our study was to identify single nucleotide polymorphisms (SNPs) associated with development of breast cancer in high-risk women treated with tamoxifen or raloxifene. Methods: We performed a nested matched case-control genome-wide association study (GWAS) in subjects entered on the P2, which included only postmenopausal women, and subjects at least 50 years old entered on the P1 phase III prevention trials who were treated with tamoxifen or raloxifene. Cases were defined as subjects who developed invasive breast cancer or ductal carcinoma in situ and each was matched to two controls based on trial (P1, P2), age at trial entry, Gail risk score, history of lobular carcinoma in situ, and time on study. The study was restricted to the 94% of subjects self-identified as Caucasian. Genotyping was performed with the Illumina Human610-Quad chip. Eigenstrat analyses were performed to control for population stratification. SNPs were imputed within 200 Kb on either side of regions containing SNPs with p ≤ 3E-05. CYP2D6 genotyping was performed on all subjects. Results: The GWAS included 592 cases and 1171 controls. 547,356 SNPs were used in the analyses after removing 14,019 for call rates less than 98%, 30,560 for minor allele frequencies <1%, and 301 with Hardy-Weinberg equilibrium p-value <1E-06. Eigenvectors did not alter the results when used as covariates. Eleven genotyped SNPs with p-values ranging from 2.12E-06 to 9.98E-06 (conditional logistic regression with eigenvector adjustment) were identified; and 22 SNPs with p < 4E-05 were identified by imputation around these SNPs on chromosomes (Chr) 4, 8, 9, 13, 16 and 22, which were then genotyped with the Invader platform. Following imputation and genotyping, initial functional genomic studies have focused on 8 SNPs on Chr 16 (p-values 1.81E-06 to 9.55E-06, with the lowest p-value for an imputed and fine mapped SNP), all of which were in ZNF423, a gene known to encode a protein that associates with SMAD family members. In lymphoblastoid cell lines genotyped for the 2 top SNPs in ZNF423 (rs8060157 and rs11076499) and stably transfected with estrogen receptor-α, the variant and wild type SNPs displayed striking differences in estradiol-induced expression of ZNF423, SMAD3, BRCA1, and BRCA2. Conclusions: This GWAS revealed SNPs associated with the development of breast cancer in high-risk women treated with tamoxifen or raloxifene. Genome-wide significance was not achieved, but SNPs in ZNF423 identified on Chr 16 were associated with differential expression of ZNF423, SMAD3, BRCA1, and BRCA2 in response to estradiol in vitro, providing direction for future research. (Supported in part by NIH grants U01GM61388, U01GM63173, P50CA116201, U10CA77202, U10CA37377, U10CA69974, U24CA114732, and the Biobank Japan Project funded by the Ministry of Education, Culture, Sports, Science and Technology, Japan) Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD05-02.
A Comparative Study in Opening and Closing Pressures of Cerebral Aneurysm Clips
Atkinson, John L. D., Piepgras, David G., Anderson, Robert E.

Mayo Clinic

Neurosurgery | April 23, 2011 | Volume: 26 | Issue: 1 | Pages: 80-85

10.1227/00006123-199001000-00011 Get It

Abstract Modern aneurysm clips with newer metallurgic properties and state-of-the-art designs have evolved through the years. Regretfully, manufacturers are still not required to provide product information regarding clip strength, and when such information is supplied, there is no interbrand consistency to how it is obtained. This experiment compares the closing pressures of 5 commonly used brands of aneurysm clips: Yasargil, Sugita, Sundt-Kees, Vari-Angle McFadden, and Heifetz. Interclip comparison is also made of opening pressures, that is, the arterial pressure required to open an aneurysm clip. Findings show a distinct difference in closing forces among these brands of aneurysm clips. The study of opening forces indicates that the important factors determining clip release or displacement were the failure of the clip to cross the vessel completely and intrinsic characteristics of the vascular wall. (Neurosurgery 26:80-85, 1990)
Cervical Vertebral Artery Aneurysms and Arteriovenous Fistulae in Neurofibromatosis Type 1: Case Reports
Piepgras, David G., Schievink, Wouter I.

Mayo Clinic

Neurosurgery | April 23, 2011 | Volume: 29 | Issue: 5 | Pages: 760-765

10.1227/00006123-199111000-00020 Get It

Abstract Neurofibromatosis is of particular interest to neurosurgeons because of the various central and peripheral nervous system tumors and, more rarely, cervicocerebral arterial lesions associated with the disease. In the present paper, we report two patients with neurofibromatosis Type 1 (von Recklinghausen's disease) who had anomalies of the extracranial vertebral arteries. A large extracranial vertebral artery' aneurysm was incidentally discovered in the first patient, a 43-year-old woman, after rupture of a subclavian artery aneurysm. The second patient, a 28-year-old woman, had an enlarging neck mass and was found to have an extensive extracranial vertebral artery arteriovenous fistula. The vascular lesions associated with neurofibromatosis Type 1 in general and those arising from the extracranial vertebral artery in particular are reviewed.
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, Marilyn S. , DeKosky, Steven T. , Dickson, Dennis W. , Dubois, Bruno , Feldman, Howard , Fox, Nick C. , Gamst, Anthony, Jagust, William J. , Petersen, Ronald C. , Snyder, Peter J. , Carrillo, María C. , Thies, Bill, Phelps, Creighton H., Holtzman, David M. , Dickson, Dennis W , Fox, Nick C , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | April 22, 2011 | Volume: 7 | Issue: 3 | Pages: 270-279

10.1016/j.jalz.2011.03.008 | PMID 21514249 Get It

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.
Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Jack, Clifford R. , Albert, Marilyn , Carrillo, María C. , Thies, Bill, Phelps, Creighton H., Knopman, David S. , McKhann, Guy M. , Sperling, Reisa Anne , Jack, Clifford R

Mayo Clinic

Alzheimer's & Dementia | April 22, 2011 | Volume: 7 | Issue: 3 | Pages: 257-262

10.1016/j.jalz.2011.03.004 | PMID 21514247 Get It

Background Criteria for the clinical diagnosis of Alzheimer's disease (AD) were established in 1984. A broad consensus now exists that these criteria should be revised to incorporate state‐of‐the‐art scientific knowledge. Methods The National Institute on Aging (NIA) and the Alzheimer's Association sponsored a series of advisory round table meetings in 2009 whose purpose was to establish a process for revising diagnostic and research criteria for AD. The recommendation from these advisory meetings was that three separate work groups should be formed with each assigned the task of formulating diagnostic criteria for one phase of the disease: the dementia phase; the symptomatic, pre‐dementia phase; and the asymptomatic, preclinical phase of AD. Results Two notable differences from the AD criteria published in 1984 are incorporation of biomarkers of the underlying disease state and formalization of different stages of disease in the diagnostic criteria. There was a broad consensus within all three workgroups that much additional work is needed to validate the application of biomarkers for diagnostic purposes. In the revised NIA‐Alzheimer's Association criteria, a semantic and conceptual distinction is made between AD pathophysiological processes and clinically observable syndromes that result, whereas this distinction was blurred in the 1984 criteria. Conclusions The new criteria for AD are presented in three documents. The core clinical criteria of the recommendations regarding AD dementia and MCI due to AD are intended to guide diagnosis in the clinical setting. However, the recommendations of the preclinical AD workgroup are intended purely for research purposes.
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Chertkow, Howard , Jack, Clifford R. , Kawas, Claudia H. , Klunk, William E. , Mayeux, Richard , Mohs, Richard C. , Morris, John C. , Rossor, Martin N. , Scheltens, Philip , Carrillo, María C. , Thies, Bill, Weıntraub, Sandra , Phelps, Creighton H., McKhann, Guy M. , Knopman, David S. , Hyman, Bradley T. , Koroshetz, Walter J. , Manly, Jennifer J. , Jack, Clifford R , Scheltens, Philip , Morris, John C

Mayo Clinic

Alzheimer's & Dementia | April 22, 2011 | Volume: 7 | Issue: 3 | Pages: 263-269

10.1016/j.jalz.2011.03.005 | PMID 21514250 Get It

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all‐cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.